Get started

Financials · NMTC

NeuroOne Medical Technologies Corporation (NMTC) financials

For the twelve months ended Jun 30, 2026, NeuroOne Medical Technologies Corporation reported $9.47M of revenue and -$7.45M of net income.

Revenue, TTM
$9.47M
Revenue growth, YoY
+42.8%
Net income, TTM
-$7.45M
Net margin
-78.6%
Free cash flow, TTM
-$7.16M
Cash
$2.05M
P/S
0.85
Market cap
$8.0M
Annual revenue$9.10M
FY2015FY2025
Annual net income-$3.61M
FY2015FY2025
Annual free cash flow-$2.92M
FY2019FY2025

NMTC revenue and earnings growth

NMTC revenueQ3 2026$1.97M

Quarter YoY
+16.3%
QoQ
+6.0%
FY YoY
+163.5%

NMTC revenue was $1.97M in fiscal Q3 2026 (ended Jun 30, 2026), up 16.3% from a year earlier and up 6.0% from the prior quarter. For the full fiscal 2025 it was $9.10M, up 163.5% from fiscal 2024. It rose in 3 of the last 4 fiscal years. Fiscal 2025 is the highest of the 12 fiscal years on file.

NMTC net incomeQ3 2026-$2.01M

NMTC net income was -$2.01M in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$1.50M a year earlier. For the full fiscal 2025 it was -$3.61M, compared with -$12.32M in fiscal 2024.

NMTC EPSQ3 2026-$0.28

NMTC diluted EPS was -$0.28 in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$0.19 a year earlier. For the full fiscal 2025 it was -$0.09.

NMTC free cash flowQ3 2026-$1.10M

NMTC free cash flow was -$1.10M in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$1.51M a year earlier. For the full fiscal 2025 it was -$2.92M, compared with -$11.13M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Sep 30, 2025
FY2024
Sep 30, 2024
FY2023
Sep 30, 2023
FY2022
Sep 30, 2022
FY2021
Sep 30, 2021
FY2020
Sep 30, 2020
FY2019
Sep 30, 2019
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
FY2015
Dec 31, 2015
Revenue$9.10M$3.45M$1.95M$171.2K$178.1K---$0$0
Cost of revenue$3.96M$2.37M$1.50M$242.0K$275.9K-----
Gross profit$5.14M$1.08M$456.5K-$70.8K-$97.7K-----
Research and development$4.98M$5.07M$6.94M$4.93M$3.93M$2.08M$1.53M$735.3K--
Selling, general and admin$7.38M$7.90M$6.93M$6.98M$6.26M$4.75M$4.28M$2.34M$32.6K$30.9K
Operating income-$4.23M-$11.89M-$11.96M-$10.03M-$10.22M-$4.90M-$5.81M-$3.07M-$32.6K-$30.9K
Interest expense----$3.1K----$14.0K
Pre-tax income-$3.61M-$12.32M-$11.86M-$10.00M--$2.02M---$32.6K-$30.9K
Income tax-----$271.1K---$0$0
Net income-$3.61M-$12.32M-$11.86M-$10.00M-$9.95M-$13.64M-$6.78M-$5.06M-$47.8K-$62.9K
EPS, basic-$0.09-$0.46-$0.65-$0.63-$0.93-$2.52-$1.71-$2.31-$0.03-$0.03
EPS, diluted-$0.09-$0.46-$0.65-$0.63-$0.93-$2.52-$1.71-$2.31-$0.03-$0.03
Diluted shares40.2M26.8M18.1M16.0M10.7M5.4M4.0M2.2M1.7M1.7M

Balance sheet

Balance sheet
Line item
FY2025
Sep 30, 2025
FY2024
Sep 30, 2024
FY2023
Sep 30, 2023
FY2022
Sep 30, 2022
FY2021
Sep 30, 2021
FY2020
Sep 30, 2020
FY2019
Sep 30, 2019
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
FY2015
Dec 31, 2015
Cash and equivalents$6.57M$1.46M$5.32M$8.16M$6.90M$4.04M$260.7K$26.5K$522.2K$0
Short-term investments---$2.98M------
Receivables$1.26M$176.6K-$33.2K$48.3K----$0
Inventory$2.23M$2.64M$1.73M$704.5K$98.3K-----
Current assets$10.23M$4.63M$7.31M$12.18M$7.29M$4.16M$301.8K$33.6K$576.0K$1.8K
Total assets$10.79M$5.37M$8.10M$12.82M$7.94M$4.76M$532.6K$250.0K$756.9K$1.8K
Current liabilities$2.30M$2.21M$1.79M$3.10M$1.18M$2.36M$1.77M$3.91M$677.2K$83.3K
Short-term debt--$129.1K--$1.01M-$253.0K$50.0K-
Long-term debt--$55.3K$119.6K$202.9K$254.3K----
Total debt--$184.4K$119.6K$202.9K$1.26M----
Total liabilities$3.71M$4.55M$1.85M$3.22M$1.38M$2.69M$1.77M$5.29M$1.02M$83.3K
Shareholders' equity$7.07M$822.0K$6.25M$9.60M$6.55M$2.07M-$1.24M-$5.04M-$266.2K-$81.5K

Cash flow

Cash flow
Line item
FY2025
Sep 30, 2025
FY2024
Sep 30, 2024
FY2023
Sep 30, 2023
FY2022
Sep 30, 2022
FY2021
Sep 30, 2021
FY2020
Sep 30, 2020
FY2019
Sep 30, 2019
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
FY2015
Dec 31, 2015
Operating cash flow-$2.84M-$11.01M-$12.89M-$7.52M-$8.60M-$3.43M-$5.40M-$2.11M-$21.1K-$30.2K
Capital expenditures$81.7K$120.2K$384.1K$275.2K$67.1K$122.4K$58.4K---
Free cash flow-$2.92M-$11.13M-$13.27M-$7.79M-$8.67M-$3.55M-$5.45M---
Investing cash flow-$81.7K-$120.2K$2.65M-$3.24M-$67.1K-$122.4K-$123.4K-$91.7K$0$0
Financing cash flow$8.03M$7.27M$7.40M$12.02M$11.53M$7.32M$5.77M$1.70M$21.1K$30.0K
Stock-based compensation$1.26M$1.34M$1.11M$947.2K--$324.2K$76.8K--
Depreciation and amortization$261.7K$246.8K$199.3K$118.6K$80.7K$47.6K$27.6K---

Key ratios

Key ratios
Line item
FY2025
Sep 30, 2025
FY2024
Sep 30, 2024
FY2023
Sep 30, 2023
FY2022
Sep 30, 2022
FY2021
Sep 30, 2021
FY2020
Sep 30, 2020
FY2019
Sep 30, 2019
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
FY2015
Dec 31, 2015
Revenue growth, YoY163.5%76.9%1040.7%-3.9%------100.0%
Gross margin56.5%31.3%23.4%-41.4%-54.9%-----
Operating margin-46.5%-344.3%-612.3%-5860.2%-5735.9%-----
Net margin-39.6%-356.7%-607.4%-5842.0%-5584.3%-----
Free cash flow margin-32.1%-322.4%-679.7%-4553.8%-4866.7%-----
Return on equity-51.0%-1498.5%-189.8%-104.1%-151.8%-660.2%----
Return on assets-33.4%-229.4%-146.5%-78.0%-125.3%-286.6%-1273.2%-2023.5%-6.3%-3420.2%
Current ratio4.442.094.083.936.171.760.170.010.850.02
Debt to equity--0.030.010.030.61----

Source: XBRL data NeuroOne Medical Technologies Corporation files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-3, first reported May 14, 2021.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

NMTC peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
NMTC$9.47M+42.8%-$7.45M-78.6%$8.0M
SYK$26.30B+7.9%$3.62B13.8%$124.05B
MMM$25.25B+1.7%$3.54B14.0%$95.67B
BSX$21.07B+8.9%$3.50B16.6%$61.96B
BDX$23.25B+17.4%$941.00M4.0%$57.71B
MDLN$30.68B-$683.00M2.2%$52.13B
RMD$5.73B+9.0%$1.59B27.8%$33.10B
DXCM$5.10B+13.0%$991.00M19.4%$29.62B
WST$3.40B+12.6%$638.90M18.8%$27.85B

NMTC FAQ

8 questions
  • What is NMTC revenue?
    NeuroOne Medical Technologies Corporation (NMTC) reported $9.47M of revenue for the twelve months ended Jun 30, 2026. That is up 42.8% from the year before. Revenue for fiscal 2025 was $9.10M.
  • Is NMTC profitable?
    No. NeuroOne Medical Technologies Corporation reported a net loss of $7.45M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does NMTC have?
    NeuroOne Medical Technologies Corporation reported $2.05M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is NMTC revenue growing?
    NeuroOne Medical Technologies Corporation's revenue changed +163.5% in fiscal 2025, to $9.10M.
  • What is NMTC gross margin?
    NeuroOne Medical Technologies Corporation's gross profit was $5.27M on $9.47M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 55.6%.
  • What is NMTC free cash flow?
    NeuroOne Medical Technologies Corporation generated -$7.16M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$7.05M less capital expenditures.
  • When did NMTC last report financial results?
    The latest statements here come from NeuroOne Medical Technologies Corporation's 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this NMTC financial data come from?
    Quantisnow builds these statements from the structured XBRL data NeuroOne Medical Technologies Corporation files with the SEC. It is provided for information only and is not investment advice.